Exagen Inc.
NASDAQ:XGNMedical - Diagnostics & Research
+$0.16 today
- Market cap
- $99.50M
- Beta
- 2.02
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$0.85
Volume 0.47M
Average 0.39M
XGN Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Exagen Inc.NASDAQ: XGN
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables rises 7.1% from a year ago
Net receivables stood at $15.77M at the end of Q1 FY2026, up 7.1% from a year earlier and up 45.3% from the prior quarter. Over 3 fiscal years it compounded at +21.3% a year.
Context
- Net receivables amounted to 30.4% of total assets at the end of Q1 FY2026, down 6.2 pp from a year earlier.
- Net receivables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +7.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 10.86M USD
- Year-over-year change
- +38.5%
- 4-year CAGR
- +3.0%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.86M | +38.5% |
| FY2024 | 2024-12-31 | 7.84M | +19.6% |
| FY2023 | 2023-12-31 | 6.55M | +7.8% |
| FY2022 | 2022-12-31 | 6.08M | -37.1% |
| FY2021 | 2021-12-31 | 9.65M | — |
Net Receivables vs competitors
How XGN compares with its peers on the latest reported figures
- XGN's Mar 2026 net receivables of $15.77M is the 4th highest of the 11 companies compared; the peer median is $12.11M.
- Its year-over-year change of +7.1% is the 8th highest of 10, against a peer median of +14.4%.
- Net receivables amounts to 30.4% of total assets for XGN, versus a peer median of 12.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $175.41M | +14.2% | +10.0% | 13.0% | |
| Mar 2026 | $56.88M | +27.5% | +17.7% | 13.1% | |
| Dec 2025 | $33.82M | — | — | 14.6% | |
| Mar 2026 | $15.77M | +7.1% | +21.3% | 30.4% | |
| Jun 2026 | $14.93M | -5.0% | +16.3% | 11.3% | |
| Mar 2026 | $13.62M | +14.4% | +19.7% | 19.7% | |
| Mar 2026 | $10.6M | +12.4% | -13.7% | 9.7% | |
| Mar 2026 | $9.62M | +122.5% | +25.9% | 17.8% | |
| Mar 2026 | $5.67M | +1.0% | +2.5% | 5.7% | |
| Mar 2026 | $4.81M | +1825.6% | +125.7% | 2.4% | |
BIOABioAge Labs, Inc. | Mar 2026 | $709K | +96.4% | — | 0.2% |
| Peer median (excluding XGN) | $12.11M | +14.4% | +17.0% | 12.1% | |
Competitors are the stored peer set for XGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 99.44M | 62.39M | 36.49M | 22.04M | 32.22M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 9.65M | 6.08M | 6.55M | 7.84M | 10.86M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 490K | 236K | 1.93M | 859K | 38K |
| Total Current Assets | 112.73M | 72.61M | 47.84M | 36.46M | 48.89M |
| Property, Plant & Equipment (Net) | 4.77M | 13.08M | 8.49M | 7.68M | 8.37M |
| Goodwill | 5.51M | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 200K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 433K | 528K | 616K | 550K | 556K |
| Total Non-current Assets | 10.71M | 13.61M | 9.1M | 8.23M | 9.13M |
| Total Assets | 123.45M | 86.22M | 56.94M | 44.69M | 58.02M |
| Account Payables | 2.49M | 3.05M | 3.13M | 4.14M | 4.15M |
| Short-term Debt | 587K | 190K | 264K | 423K | 3M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 675K |
| Other Current Liabilities | 2.19M | 445K | 0 | 0 | 6.33M |
| Total Current Liabilities | 9.32M | 9.62M | 11.9M | 13.51M | 14.16M |
| Long-term Debt | 27.48M | 28.78M | 19.23M | 19.82M | 22.26M |
| Deferred Tax Liabilities | 306K | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 1.41M | 867K | 357K | 157K | 3.71M |
| Total Non-current Liabilities | 29.19M | 34.14M | 22.35M | 21.64M | 26.41M |
| Total Liabilities | 38.51M | 43.76M | 34.25M | 35.15M | 40.57M |
| Common Stock | 16K | 17K | 17K | 18K | 23K |
| Retained Earnings | (208.14M) | (255.53M) | (279.22M) | (294.33M) | (314.28M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 84.94M | 42.46M | 22.69M | 9.54M | 17.45M |
| Total Debt | 28.07M | 35.2M | 23.23M | 23.01M | 25.71M |
| Net Debt | (71.38M) | (27.19M) | (13.26M) | 969K | (6.51M) |
Exagen Inc.
NASDAQ:XGN
Intrinsic Alpha fair value
Locked
Current Price
$3.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.